-
Something wrong with this record ?
Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study
D. Horakova, R. Zivadinov, B. Weinstock-Guttman, E. Havrdova, J. Qu, M. Tamaño-Blanco, D. Badgett, M. Tyblova, N. Bergsland, S. Hussein, L. Willis, J. Krasensky, M. Vaneckova, Z. Seidl, P. Lelkova, MG. Dwyer, M. Zhang, H. Yu, X. Duan, T....
Language English Country United States
Document type Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
Grant support
NT13237
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Cytomegalovirus immunology MeSH
- Adult MeSH
- HLA-DRB1 Chains genetics MeSH
- Cohort Studies MeSH
- Smoking adverse effects MeSH
- Humans MeSH
- Longitudinal Studies MeSH
- Young Adult MeSH
- Disease Progression MeSH
- Prospective Studies MeSH
- Antibodies, Viral blood MeSH
- Risk Factors MeSH
- Multiple Sclerosis etiology immunology virology MeSH
- Epstein-Barr Virus Nuclear Antigens immunology MeSH
- Environment MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
OBJECTIVES: To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event. METHODS: We analyzed 211 CIS patients (age: 28.9±7.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months. RESULTS: The time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies. CONCLUSIONS: Relapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031708
- 003
- CZ-PrNML
- 005
- 20181023152659.0
- 007
- ta
- 008
- 131002s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0053996 $2 doi
- 035 __
- $a (PubMed)23320113
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Horáková, Dana $u Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. $7 xx0076527
- 245 10
- $a Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study / $c D. Horakova, R. Zivadinov, B. Weinstock-Guttman, E. Havrdova, J. Qu, M. Tamaño-Blanco, D. Badgett, M. Tyblova, N. Bergsland, S. Hussein, L. Willis, J. Krasensky, M. Vaneckova, Z. Seidl, P. Lelkova, MG. Dwyer, M. Zhang, H. Yu, X. Duan, T. Kalincik, M. Ramanathan,
- 520 9_
- $a OBJECTIVES: To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event. METHODS: We analyzed 211 CIS patients (age: 28.9±7.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months. RESULTS: The time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies. CONCLUSIONS: Relapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a protilátky virové $x krev $7 D000914
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a Cytomegalovirus $x imunologie $7 D003587
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a životní prostředí $7 D004777
- 650 _2
- $a virus Epsteinův-Barrové - jaderné antigeny $x imunologie $7 D019309
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a HLA-DRB1 řetězec $x genetika $7 D059811
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a longitudinální studie $7 D008137
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a roztroušená skleróza $x etiologie $x imunologie $x virologie $7 D009103
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a kouření $x škodlivé účinky $7 D012907
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zivadinov, Robert $u -
- 700 1_
- $a Weinstock-Guttman, Bianca $u -
- 700 1_
- $a Kubala Havrdová, Eva, $u - $d 1955- $7 nlk19990073204
- 700 1_
- $a Qu, Jun $u -
- 700 1_
- $a Tamaño-Blanco, Miriam $u -
- 700 1_
- $a Badgett, Darlene $u -
- 700 1_
- $a Týblová, Michaela $u - $7 xx0121850
- 700 1_
- $a Bergsland, Niels $u -
- 700 1_
- $a Hussein, Sara $u -
- 700 1_
- $a Willis, Laura $u -
- 700 1_
- $a Krásenský, Jan $u - $7 xx0096156
- 700 1_
- $a Vaněčková, Manuela, $u - $d 1973- $7 mzk2007377403
- 700 1_
- $a Seidl, Zdeněk, $u - $d 1950- $7 mzk2004258727
- 700 1_
- $a Lelková, Petra $u - $7 xx0142909
- 700 1_
- $a Dwyer, Michael G $u -
- 700 1_
- $a Zhang, Ming $u -
- 700 1_
- $a Yu, Haoying $u -
- 700 1_
- $a Duan, Xiaotao $u -
- 700 1_
- $a Kalincik, Tomas $u -
- 700 1_
- $a Ramanathan, Murali $u -
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 8, č. 1 (2013), s. e53996
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23320113 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20181023153206 $b ABA008
- 999 __
- $a ok $b bmc $g 995795 $s 830153
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 8 $c 1 $d e53996 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- GRA __
- $p MZ0 $a NT13237
- LZP __
- $a Pubmed-20131002